Copyright
©The Author(s) 2021.
World J Clin Oncol. Jun 24, 2021; 12(6): 468-481
Published online Jun 24, 2021. doi: 10.5306/wjco.v12.i6.468
Published online Jun 24, 2021. doi: 10.5306/wjco.v12.i6.468
Table 1 Exercise progression in the Get REAL & HEEL Exercise Program
| Aerobic exercise | Week 1-2 | Week 3-7 | Week 8-16 |
| Duration (min) | 10-15 | 10-30 | 30 |
| Intensity | Low | Moderate | |
| RPE | 8-11 | 12-14 | |
| Resistance exercise | Week 1-2 | Week 3-7 | Week 8-16 |
| Duration (min) | ~30 | ||
| Intensity | Low to moderate | High | |
| RPE | 7-13 | 14-15 | |
| Sets x Reps / exercise | 1 x 15 | 2 x 10 - 15 | 2 x 10 |
Table 2 Baseline characteristics – mean (SD)
| Breast cancer (n = 31) | Control (n = 15) | Total (n = 46) | |
| Demographics | |||
| Age (yr) | 54 (12) | 55 (8) | 54 (11) |
| Height (cm) | 167 (7) | 162 (7)1 | 165 (8) |
| Weight (kg) | 77 (12) | 75 (14) | 76 (13) |
| BMI categories (kg/m2) | |||
| Normal (18.5 to < 25) | 29% | 13% | 24% |
| Overweight (25 to < 30) | 48% | 60% | 52% |
| Obese (30 to < 35) | 10% | 7% | 9% |
| Obese II (≥ 35) | 13% | 20% | 15% |
| Body fat (%) | 41 (6) | 40 (4) | 41 (5) |
| Lean mass (kg) | 42 (6) | 42 (7) | 42 (6) |
| Postmenopausal (%) | 65% | 67% | 65% |
| Race (Caucasian, %) | 87% | 100% | 91% |
| Clinical variables | |||
| VO2peak (mL/kg/min) | 20.9 (5.3) | 22.4 (2.8) | 21.4 (4.6) |
| Time toexertion (mm:ss) | 9:41 (1:42) | 10:21 (1:20) | 9:54 (1:36) |
| Peak power (Watt) | 120 (26) | 130 (20) | 123 (24) |
| Six minute walk (m) | 538 (72) | 557 (53) | 544 (67) |
| Timed up & go (sec) | 4.8 (1.2) | 3.9 (0.7)1 | 4.5 (1.2) |
| Breast cancer details | |||
| Tumor stage | |||
| 0 | 3% | -- | -- |
| I | 27% | -- | -- |
| II | 47% | -- | -- |
| III | 23% | -- | -- |
| HR status | |||
| ER positive | 81% | -- | -- |
| HER2 status | |||
| Positive (all received trastuzumab) | 26% | -- | -- |
| Surgery | |||
| Lumpectomy | 71% | -- | -- |
| Mastectomy | 29% | -- | -- |
| Cardiotoxic therapies | |||
| Anthracycline | 23% | -- | -- |
| Trastuzumab | 26% | -- | -- |
| Anthra + Tras | 3% | -- | -- |
| Endocrine therapy | |||
| Aromatase inhibitor | 45% | -- | -- |
| Tamoxifen | 19% | -- | -- |
| Days since end of primary treatment | 101 (91) | -- | -- |
Table 3 Attendance and compliance (out of 48 total days of training opportunity)
| Breast cancer mean (SD) (n = 31) | Control mean (SD) (n = 15) | Cohen’s d | P value | |
| Intervention Attendance (days) | 35 (9) | 33 (9) | 0.22 | 0.420 |
| Aerobic Compliance (days) | 26 (10) | 32 (9) | -0.63 | 0.060 |
| Strength Compliance (days) | 14 (5) | 18 (3) | -1.00 | 0.011 |
- Citation: Lee JT, Wagoner CW, Sullivan SA, Amatuli DJ, Nyrop KA, Hanson ED, Stoner L, Jensen BC, Muss HB, Battaglini CL. Impact of community-based exercise program participation on aerobic capacity in women with and without breast cancer. World J Clin Oncol 2021; 12(6): 468-481
- URL: https://www.wjgnet.com/2218-4333/full/v12/i6/468.htm
- DOI: https://dx.doi.org/10.5306/wjco.v12.i6.468